Blood phenotype O and indirect bilirubin are associated with lower, early COVID-19—related mortality: A retrospective study

Efat, Alaa; Shoeib, Sabry; Elkholy, Aly; Aboelela, Osama Saied Hussein; Elshamy, Doaa

doi:10.1177/03946320221133952

Cited by 2 publications

(1 citation statement)

References 31 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hyperchloremia was significantly associated with increased risks of kidney injury, endotracheal intubation, and death; however, it was not associated with increased ferritin, CRP, or hemoglobin decreases in critically ill COVID-19 patients [54]. Direct bilirubin was found to be one of the best predictors for mortality in cases with COVID-19, so indirect bilirubin may be considered a good protector against complications of the infection [55,56]. CK-NAC and CK-MB increases signify serious cardiovascular complications in COVID-19 patients [57].…”

Section: Resultsmentioning

confidence: 90%

Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study

Goncharov,

Avdonin,

Voitenko

et al. 2023

Metabolites

View full text Add to dashboard Cite

During the initial diagnosis of urgent medical conditions, which include acute infectious diseases, it is important to assess the severity of the patient’s clinical state as quickly as possible. Unlike individual biochemical or physiological indicators, derived indices make it possible to better characterize a complex syndrome as a set of symptoms, and therefore quickly take a set of adequate measures. Recently, we reported on novel diagnostic indices containing butyrylcholinesterase (BChE) activity, which is decreased in COVID-19 patients. Also, in these patients, the secretion of von Willebrand factor (vWF) increases, which leads to thrombosis in the microvascular bed. The objective of this study was the determination of the concentration and activity of vWF in patients with COVID-19, and the search for new diagnostic indices. One of the main objectives was to compare the prognostic values of some individual and newly derived indices. Patients with COVID-19 were retrospectively divided into two groups: survivors (n = 77) and deceased (n = 24). According to clinical symptoms and computed tomography (CT) results, the course of disease was predominantly moderate in severity. The first blood sample (first point) was taken upon admission to the hospital, the second sample (second point)—within 4–6 days after admission. Along with the standard spectrum of biochemical indicators, BChE activity (BChEa or BChEb for acetylthiocholin or butyrylthiocholin, respectively), malondialdehyde (MDA), and vWF analysis (its antigen level, AGFW, and its activity, ActWF) were determined and new diagnostic indices were derived. The pooled sensitivity, specificity, and area under the receiver operating curve (AUC), as well as Likelihood ratio (LR) and Odds ratio (OR) were calculated. The level of vWF antigen in the deceased group was 1.5-fold higher than the level in the group of survivors. Indices that include vWF antigen levels are superior to indices using vWF activity. It was found that the index [Urea] × [AGWF] × 1000/(BChEb × [ALB]) had the best discriminatory power to predict COVID-19 mortality (AUC = 0.91 [0.83, 1.00], p < 0.0001; OR = 72.0 [7.5, 689], p = 0.0002). In addition, [Urea] × 1000/(BChEb × [ALB]) was a good predictor of mortality (AUC = 0.95 [0.89, 1.00], p < 0.0001; OR = 31.5 [3.4, 293], p = 0.0024). The index [Urea] × [AGWF] × 1000/(BChEb × [ALB]) was the best predictor of mortality associated with COVID-19 infection, followed by [Urea] × 1000/(BChEb × [ALB]). After validation in a subsequent cohort, these two indices could be recommended for diagnostic laboratories.

show abstract

Section: Resultsmentioning

confidence: 90%